Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Innovation Pharmaceuticals Inc (IPIX)

Innovation Pharmaceuticals Inc (IPIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch Watch
Help
Go To:
Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate ACCESS Newswire - Fri Jul 22, 2022

WAKEFIELD, MA / ACCESSWIRE / July 22, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on the Company's Brilacidin program...

IPIX : 0.0007 (-53.33%)
Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium ACCESS Newswire - Tue Jun 28, 2022

WAKEFIELD, MA / ACCESSWIRE / June 28, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced new antiviral research on Brilacidin in...

IPIX : 0.0007 (-53.33%)
Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers ACCESS Newswire - Thu Jun 23, 2022

WAKEFIELD, MA / ACCESSWIRE / June 23, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported that Brilacidin, the Company's defensin-mimetic...

IPIX : 0.0007 (-53.33%)
Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology ACCESS Newswire - Wed Jun 15, 2022

WAKEFIELD, MA / ACCESSWIRE / June 15, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that the Company has acquired a minority...

IPIX : 0.0007 (-53.33%)
Innovation Pharmaceuticals Announces Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin ACCESS Newswire - Tue Mar 15, 2022

- In other news, Scientific Advisor, William F. DeGrado, PhD, gives keynote lecture at 2021 Faraday Discussion and co-awarded John Scott Medal WAKEFIELD, MA / ACCESSWIRE / March 15, 2022 / Innovation Pharmaceuticals...

IPIX : 0.0007 (-53.33%)
Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases ACCESS Newswire - Mon Mar 7, 2022

WAKEFIELD, MA / ACCESSWIRE / March 7, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported findings from data review of the Company's...

IPIX : 0.0007 (-53.33%)
Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022 ACCESS Newswire - Tue Dec 7, 2021

WAKEFIELD, MA / ACCESSWIRE / December 7, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provides shareholders with perspectives on the...

IPIX : 0.0007 (-53.33%)
Innovation Pharmaceuticals' COVID-19 Clinical Trial Topline Results Anticipated to Be Reported the Week of November 8th ACCESS Newswire - Mon Oct 25, 2021

WAKEFIELD, MA / ACCESSWIRE / October 25, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced the Company anticipates reporting topline...

IPIX : 0.0007 (-53.33%)
Innovation Pharmaceuticals Provides Update on COVID-19 Clinical Trial, Compassionate Use Requests and Research into Brilacidin's Broad-Spectrum Antiviral Properties ACCESS Newswire - Thu Sep 23, 2021

WAKEFIELD, MA / ACCESSWIRE / September 23, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on the status of its randomized,...

IPIX : 0.0007 (-53.33%)

Barchart Exclusives

3 Top Dividend Stocks to Buy in September Barchart - Tue Sep 1, 6:30PM CDT
Chevron, Realty Income, and NextEra bring more than just yield to the table. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.